☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - February 2011

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Capsaicin cutaneous patches (Qutenza®) have been accepted for restricted use for the treatment of peripheral neuropathic pain in non-diabetic adults who have not achieved adequate pain relief from, or who have not tolerated, conventional first and second-line treatments. Treatment should be under the supervision of a specialist in pain management.

Fenticonazole (Ginoxin®) has been rejected for use in the treatment of vulvovaginal candidiasis. The manufacturer failed to make a submission.

Ivabradine (Procoralan®) has been rejected for the treatment of symptomatic chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm, in combination with beta-blockers, in patients inadequately controlled with an optimal beta-blocker dose and whose heart rate is > 60 bpm. The manufacturer failed to make a submission.

Miconazole buccal tablets (Loramyc®) have been rejected, following a resubmission, for the treatment of oropharyngeal candidiasis in immunocompromised patients. The manufacturer failed to provide a sufficiently robust clinical and economic analysis to gain acceptance.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - February 2011' by emailShare 'SMC Update - February 2011' on FacebookShare 'SMC Update - February 2011' on TwitterShare 'SMC Update - February 2011' on LinkedInShare 'SMC Update - February 2011' on reddit


No Comments to “SMC Update - February 2011”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.